Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30876198 | 1.00 | CA12 (0.44) | CA12CA1CA7CA9CA2 | |
| SCHEMBL31036121 | 0.82 | CA12 (0.55) | CA12CA1CA7CA9CA2 | |
| Calanone SCHEMBL29894123 | 0.77 | PDE4D (0.43) | CA12CA1CA7CA9CA2 | |
| SCHEMBL2146882 | 0.77 | CYP3A4 (0.37) | CA12CA1CA7CA9CA2 | |
| Soulattrolide SCHEMBL2040583 | 0.71 | ALDH1A1 (0.67) | CA12CA1CA7CA9CA2 | |
| Soulattrolide SCHEMBL6731413 | 0.71 | ALDH1A1 (0.67) | CA12CA1CA7CA9CA2 | |
| Soulattrolide SCHEMBL8698180 | 0.71 | ALDH1A1 (0.67) | CA12CA1CA7CA9CA2 | |
| SCHEMBL8702867 | 0.70 | ALDH1A1 (0.45) | CA12CA1CA7CA9CA2 | |
| SCHEMBL8698429 | 0.70 | ALDH1A1 (0.45) | CA12CA1CA7CA9CA2 | |
| SCHEMBL2146475 | 0.70 | ALDH1A1 (0.41) | CYP3A4ALDH1A1MAPTKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3346842-B1 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | NOVONESIS PLANT BIOSOLUTIONS AS (DK) | 2026-03-25 | — | — | EP | claimed |
| EP-4714440-A2 | A HEALING HERBAL-MINERAL COMPOSITION WITH ENHANCED EFFECTS | Kurek, Janusz (PL) | 2026-03-25 | — | — | EP | claimed |
| US-11560342-B2 | Bacillus isolates and uses thereof | MONSANTO TECHNOLOGY, LLC (US) | 2023-01-24 | — | — | US | claimed |
| EP-3801017-A1 | METHODS OF PROTECTING A PLANT FROM INSECT PESTS | Novozymes Bioag A/S (DK) | 2021-04-14 | — | — | EP | claimed |
| EP-3801030-A1 | METHODS OF PROTECTING A PLANT FROM FUNGAL PESTS | Novozymes BioAG A/S (DK) | 2021-04-14 | — | — | EP | claimed |
| US-20210068401-A1 | BACILLUS ISOLATES AND USES THEREOF | MONSANTO TECHNOLOGY LLC (US) | 2021-03-11 | — | — | US | claimed |
| US-20200405797-A1 | TRANSMUCOSAL DELIVERY DEVICE AND METHOD OF MANUFACTURING SAME | NANOSTRIPS, INC. (US) | 2020-12-31 | — | — | US | claimed |
| EP-3749094-A2 | METHODS OF PROTECTING A PLANT FROM FUNGAL PESTS | Novozymes BioAG A/S (DK) | 2020-12-16 | — | — | EP | claimed |
| EP-3599864-A1 | COMBINATIONS OFYERSINIA ENTOMOPHAGA | Novozymes Bioag A/S (DK) | 2020-02-05 | — | — | EP | claimed |
| EP-3565886-A1 | BACILLUS ISOLATES AND USES THEREOF | Novozymes BioAG A/S (DK) | 2019-11-13 | — | — | EP | claimed |
| WO-2017044545-A1 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | NOVOZYMES BIOAG A/S (DK) | 2017-03-16 | — | — | WO | claimed |
| WO-2017044473-A1 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | NOVOZYMES BIOAG A/S (DK) | 2017-03-16 | — | — | WO | claimed |
| US-20160331722-A1 | Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders | GLOBAL BIOLIFE INC. | 2016-11-17 | — | — | US | claimed |
| EP-3065545-A1 | COMPOSITIONS AND METHODS FOR TREATING PESTS | Novozymes Bioag A/S (DK) | 2016-09-14 | — | — | EP | claimed |
| CN-105705013-A | Compositions and methods for treating pests | 诺维信生物农业公司 | 2016-06-22 | — | — | CN | claimed |
| US-20160050921-A1 | COMPOSITIONS AND METHODS FOR ENHANCING PLANTH GROWTH | NOVOZYMES BIOAG A/S (DK) | 2016-02-25 | — | — | US | claimed |
| EP-2978314-A1 | COMPOSITIONS AND METHODS FOR ENHANCING PLANT GROWTH | Novozymes Bio AG A/S (DK) | 2016-02-03 | — | — | EP | claimed |
| CN-105050402-A | Compositions and methods for enhancing plant growth | NOVOZYMES BIOAG AS | 2015-11-11 | — | — | CN | claimed |
| WO-2015069708-A1 | COMPOSITIONS AND METHODS FOR TREATING PESTS | NOVOZYMES BIOAG A/S (DK) | 2015-05-14 | — | — | WO | claimed |
| WO-2014160826-A1 | COMPOSITIONS AND METHODS FOR ENHANCING PLANT GROWTH | NOVOZYMES BIOAG A/S (DK) | 2014-10-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210068401-A1 | BACILLUS ISOLATES AND USES THEREOF | BLVRB, BROX, GLB1 | CA12 3113/4885CA1 2763/4885CA7 1255/4885 |
| US-20160050921-A1 | COMPOSITIONS AND METHODS FOR ENHANCING PLANTH GROWTH | MYB, ERH, BLVRB | CA12 4330/4885CA1 4270/4885CA7 2556/4885 |
| US-11560342-B2 | Bacillus isolates and uses thereof | BLVRB, BROX, GLB1 | CA12 3113/4885CA1 2763/4885CA7 1255/4885 |
| US-20160331722-A1 | Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders | HRH2, HRH3, HRH4 | CA12 3701/4885CA1 4371/4885CA7 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.